Abstract. Phosphatase and tensin homolog (PTEN) is a tumor suppressor that inhibits PI3K/Akt signaling. To examine the effect of PTEN on breast cancer cell proliferation, we expressed PTEN in MDA-MB-468 cells (MDA-MB-468 PTEN) by retroviral infection and tested the cell proliferation rate. We found that the growth rate of MDA-MB-468 PTEN cells was significantly lower than that of MDA-MB-468 control vector cells (MDA-MB-468 vec). When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a >60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells. FACS analysis demonstrated that the subG0/G1 apoptotic fraction was significantly increased in MDA-MB-468 PTEN cells after U0126 treatment, while LY294002 treatment in both cell lines and U0126 treatment in MDA-MB-468 vec cells led to a modest increase in the apoptotic fraction. This phenomenon was accompanied by the down-regulation of p-Erk. p-Erk levels were significantly lower after U0126 treatment in MDA-MB-468 PTEN cells. Similar results were observed in MDA-MB-231 cells, which express endogenous PTEN. The growth of MDA-MB-231 cells was significantly inhibited after U0126 treatment, compared to LY294002, while PTEN-null ZR-75-1 cells did not show increased sensitivity to U0126 over LY294002. Taken together, these findings suggest that blockade of PI3K/Akt signaling by PTEN may render breast cancer cells more dependent on the MEK/Erk pathway for their proliferation and survival.
Introduction
The phosphatidylinositol 3-kinase (PI3K) and Ras/Raf signaling pathways are mutated in many human cancers (1) . Activated PI3K induces the conversion of the plasma membrane lipid phosphatidylinositol (4,5)-bisphosphate (PIP 2 ) to phosphatidylinositol (3, 4, 5) -triphosphate (PIP 3 ) by phosphorylation at the D-3 position of the inositol ring (2) . A 3-phosphoinositide-dependent protein kinase, PDK1, is then activated by PIP 3 , resulting in phosphorylation of the activation loop of Akt at Thr308 (3) . Upstream signaling can also activate mammalian target of rapamycin (mTOR) complex 2 (mTORC2) and mTORC2 phosphorylates the hydrophobic motif of Akt at Ser473 to fully activate Akt (4, 5) . Activated Akt plays very important roles in cell survival, cell growth, cell proliferation, angiogenesis and cellular metabolism (5) . Phosphatase and tensin homolog (PTEN) down-regulates Akt activation by dephosphorylation of PIP 3 at the D-3 position of the inositol ring (6) .
Mitogen-activated protein kinases (MAPKs) are a family of Ser/Thr protein kinases that are involved in many cellular functions, such as proliferation, differentiation, inflammation, cell movement and cell death (7) . MAPKs are phosphorylated and activated by MAPK-kinases (MAPKKs) and phosphorylate various targets, including transcription factors and MAPK-activated protein kinases (MAPKAPKs). MAPKs are dephosphorylated and inactivated by a family of MAPKphosphatases (MKPs). MAPKKs are phosphorylated and activated by MAPKK-kinases (MAPKKKs). The MAPKKKs are then activated by interaction with a family of small GTPases and/or other protein kinases, connecting the MAPK module to cell surface receptors or external stimuli (growth factors, mitogens, stress) (8) . There are six distinct groups within the MAPK family in mammals, including extracellular signal-regulated kinases 1 and 2 (Erk1/2), c-Jun-N-terminal kinases (JNKs), p38, Erk5, Erk3/4 and Erk7/8 (8) (9) (10) .
The PTEN gene, a novel tumor suppressor, is localized to chromosome 10q23.3 and shares extensive homology with the cytoskeletal protein, tensin (11) . A high frequency of mutations at the PTEN locus has been described in cancers of the brain, breast and prostate (12) . Reportedly, PTEN not only antagonizes tumorigenesis, but also sensitizes cancer cells to chemotherapy and decreases drug resistance (13) (14) (15) .
Based on the key roles of PTEN and PI3K/Akt in cancer, we investigated the potential therapeutic role of PTEN in breast cancer. We reconstructed PTEN in PTEN-null MDA-MB-468 breast cancer cells (MDA-MB-468 PTEN) by retroviral infection and compared the proliferation rate and phosphorylation status of signaling effector molecules between MDA-MB-468 PTEN cells and MDA-MB-468 control vector (MDA-MB-468 vec) cells. We also investigated the effects of the PI3K/Akt inhibitor LY294002 and the MEK/Erk inhibitor U0126 on cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec cells.
Materials and methods
Cell culture. MDA-MB-468 vec and MDA-MB-468 PTEN cells were developed as described by Bianco et al (16) and were cultured in DMEM/F12 (Gibco, Carlsbad, CA, USA) (1:1). MDA-MB-231, ZR-75-1 and 293T cells were cultured in DMEM (Gibco). All media contained 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (Welgene, Daegu, Korea). All cell lines were incubated at 37˚C with 5% CO 2 in a humidified atmosphere.
Antibodies and reagents. Akt, p-Akt (Ser473), c-Raf, p-c-Raf, MEK, p-MEK and ß-actin antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). PTEN, Erk and p-Erk antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). LY294002 and U0126 were obtained from Calbiochem (Gibbstown, NJ, USA).
Proliferation assays. Cells were seeded at a density of 5x10 4 cells/well in a 12-well dish. Cells were trypsinized and counted in triplicate using a hemocytometer for 5 days.
Western blotting and immunoprecipitation. Cells were washed once with phosphate-buffered saline (PBS) and lysed in a lysis buffer [20 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1% Triton X-100, 0.1% SDS, 20 mM NaF, 1 mM Na 3 VO 4 and 1X protease inhibitor (Roche)]. All protein samples were resolved using 10% SDS-PAGE after boiling for 10 min in SDS sample buffer. For Western blot analysis, proteins were electro-transferred onto nitrocellulose membranes over the course of 2 h. The membranes were blocked with 5% skim milk in TBST for 1 h and incubated with appropriated dilutions of primary antibody in TBST containing 5% bovine serum albumin (BSA) overnight. The membranes were then washed three times with TBST and incubated with secondary antibody solution for 2 h. Blots were visualized with the WEST-ZOL-plus detection system (iNtRON Biotechnology, Seoul, Korea).
Cell cycle analyses by flow cytometry. Cells were harvested with 0.25% trypsin and washed once with PBS. After centrifugation, cells were fixed in 100% ice-cold methanol overnight at -20˚C. Cells were incubated in 50 μg/ml propidiumiodide (PI) in PBS and 1 mg/ml RNAase in PBS for 30 min. Cell cycle analysis was performed using FACS calibur (Becton-Dickinson Biosciences, Mountain View, CA, USA), and the data was analyzed using Cell Quest software. Each experiment was repeated three times. expected, we did not find PTEN expression in MDA-MB-468 vec cells, but found strong p-Akt activity as a result of the loss of functional PTEN (Fig. 3) . When the PI3K/Akt inhibitor LY294002 was added, down-regulation of p-Akt occurred in MDA-MB-468 vec cells. Interestingly, when the MEK/Erk inhibitor U0126 was added, the level of p-Erk did not change in MDA-MB-468 vec cells, but was dramatically lower in MDA-MB-468 PTEN cells as early as 30 min after treatment (Fig. 3) . This suggests that PTEN expression confers sensitivity to the MEK/Erk inhibitor in the down-regulation of p-Erk in MDA-MB-468 cells. In our study, Erk activation was significantly decreased only when both PI3K/Akt signaling and MEK/Erk were blocked by PTEN expression and U0126 treatment, respectively. On the other hand, Erk was constantly activated in MDA-468 vec cells, even in the presence of either LY294002 or U0126, as well as in MDA-468 PTEN cells in the presence of LY294002. Interestingly, phosphorylation of c-Raf and MEK (upstream kinases of Erk) was significantly lower in MDA-MB-468 PTEN cells, as compared with MDA-MB-468 vec cells (Fig. 4) . Overexpression of PTEN decreased phosphorylation of c-Raf both at Ser338 [which is required for Raf activation (17) ] and Ser259 [an Akt consensus inhibitory phosphorylation site in a regulatory domain of c-Raf (18) ]. This finding suggests that Erk may be activated by a Raf/MEK-independent pathway in MDA-MB-468 PTEN cells.
Results

PTEN expression down-regulates
Cell cycle analysis of MDA-MB-468 PTEN and MDA-MB-468 vec following treatment with LY294002 and U0126.
For cell cycle analysis, MDA-MB-468 PTEN and MDA-MB-468 vec cells were treated with LY294002 and U0126 at a concentration of 10 μM for 48 h, and propodium iodide-labeled nuclei were analyzed by flow cytometry. We found that the subG0/G1 apoptotic fraction was significantly higher in MDA-MB-468 PTEN cells after U0126 treatment for 48 h, while LY294002 treatment in both cell lines and U0126 treatment in MDA-MB-468 vec cells led to a modest increase in the apoptotic fraction (Fig. 5) . This indicates that the decrease in proliferation rate of MDA-MB-468 PTEN cells following U0126 treatment may be due to an increase in apoptotic cell death in these cells. Moreover, we found a proteolytic cleavage form of caspase-3 (an apoptosis marker) only following treatment with U0126 in MDA-MB-468 PTEN cells (Fig. 6 ). This suggests that the synergy between the inhibition of PI3K/Akt by PTEN and the blockade of MEK/Erk by U0126 induces apoptosis, resulting in significant inhibition of cell growth in MDA-MB-468 PTEN cells. mutation in the other allele (19) and express very low levels of PTEN (Fig. 7A) . As expected, p-Akt activity was lower in MDA-MB-231 cells than in ZR-75-1 cells (Fig. 7A ). In accordance with the previous results with MDA-MB-468 cells, treatment with LY294002 resulted in a ~25% reduction in cell proliferation after 96 h in both cell lines, while U0126 treatment led to a >45% reduction in MDA-MB-231 cells (Fig. 7B ) and a 25% reduction in ZR-75-1 cells (Fig. 7C) . This indicates that endogenous PTEN also confers sensitivity to MEK/Erk inhibition for the blockade of cell proliferation in breast cancer cells. Moreover, we also found that U0126 treatment inhibited the activation of Erk (p-Erk) in MDA-MB-231 cells (Fig. 7A) , suggesting that natural PTEN and U0126 treatment combine to block the phosphorylation of Erk and inhibit cell growth.
The effect of LY294002 and U0126 on cell proliferation rate in MDA-MB-231 and ZR-
Discussion
In this study, we investigated the role of PTEN as a sensitizer for MEK/Erk inhibition, which then results in a decrease in cell proliferation and a reduction in p-Erk activity in MDA-MB-468 breast cancer cells. MDA-MB-468 cells lack PTEN expression and function due to a frameshift mutation in one PTEN allele and loss of the other PTEN allele (20) . Accordingly, we used this cell line for our study and expressed PTEN through retroviral infection. Our data indicate that MDA-MB-468 PTEN cells (which artificially express PTEN) grew slowly, compared to MDA-MB-468 vec cells, suggesting that PTEN acts as a growth suppressor. Interestingly, the presence of PTEN generated a greater sensitivity to the MEK/ Erk inhibitor U0126, compared to the PI3K/Akt inhibitor, LY294002. On the other hand, the growth of MDA-MB-468 vec cells, which do not express PTEN, was only slightly inhibited by LY294002 and U0126; this suggests that PTEN sensitizes breast cancer cells to the MEK/Erk inhibitor for the blockade of cell proliferation (Fig. 2) . Notably, this strong growth inhibition of MDA-MB-468 PTEN cells following U0126 treatment was followed by an increase in apoptosis (Fig. 5) .
The MEK/Erk pathway appears to engage in cross-talk with the PI3K/Akt/PTEN signaling pathway. It has been reported that PTEN inhibits the integrin-and growth factor-ONCOLOGY REPORTS 24: 787-793, 2010 Figure 6 . Effects of PI3K/Akt and MEK/ERK inhibitors on the cleavage of caspase-3. Cells were seeded at a density of 1x10 6 cells/dish in 100 mm dishes. The cells were then treated with LY294002 (10 μM) or U0126 (10 μM) for 48 h. After treatment, the cells were subjected to Western blot analyses with caspase-3 antibodies. mediated Erk signaling pathways (21) . It has also been observed that there is cross-talk between the PI3K/Akt and MEK/Erk pathways in cell growth: inhibition of PI3K or MEK slowed the differentiation of immature MoDCs and induced apoptosis in 10-30% of cultured cells, while inhibition of both PI3K and MEK resulted in apoptosis in 70% of the cells (22) . Similarly, our data confirmed that there is crosstalk between PTEN and inhibition of the MEK/Erk signaling pathway, as the combination induces stronger cell growth inhibition and weaker p-Erk activity.
Erk is phosphorylated and activated by Ras/Raf/MEK signaling, and p-Erk regulates cell proliferation and differentiation (23, 24) . However, it should be noted that Erk is also activated by Raf-or MEK-independent pathways. In this study, we observed that PTEN suppressed the expression of both p-Raf and p-MEK while failing to decrease p-Erk activity in MDA-MB-468 cells (Figs. 3 and 4) . Erk was constantly activated in MDA-MB-468 vec cells in all conditions and in MDA-MB-468 PTEN cells in the presence or absence of LY294002. The inhibition of Erk activation occurred only in MDA-MB-468 PTEN cells treated with U0126, suggesting that only the combined inhibition of PI3K and MEK was able to down-regulate Erk activity. In the presence of high PI3K activity due to PTEN mutation, p-Erk appears to be regenerated via Raf/MEK-independent pathways in MDA-MB-468 cells. Interestingly, overexpression of PTEN down-regulated the phosphorylation of c-Raf at both the inhibitory (Ser259) and activating (Ser338) sites (Fig. 4) . The inhibition of phosphorylation of c-Raf at Ser259 (the Akt consensus site) maybe not directly mediated by the inhibition of Akt activity by PTEN in MDA-MB-231 PTEN cells because inhibition of p-Akt by LY294002 did not efficiently block c-Raf phosphorylation at Ser259 in MDA-MB-231 vec cells (Fig. 4) . Indeed, previous reports indicate that the inhibition of Raf/MEK/Erk by Akt may be not the universal mechanism. Laprise et al (25) reported that PI3K/Akt inhibition results in activation of the Raf/MEK/Erk pathway in differentiating enterocytes, but not in proliferative cells.
It has been reported that PKC· may activate MEK independent of Raf and Ras to trigger sustained Erk signaling and cell cycle arrest of HepG2 induced by TPA (26) . It was also reported that Epigallocatechin-3-gallate inhibits PC-3 prostate cancer cell proliferation via MEK-independent Erk1/2 activation (27) . Moreover, there is evidence of MEK-independent pathways that regulate the prolonged activation of Erk by platelet-derived growth factor signaling (28) . In agreement with these previous reports, our data indicate that Erk can be activated in Raf/MEK-independent manner in MDA-MB-468 cells. The inhibitory effect of ectopic PTEN on the phosphorylation of c-Raf and c-MEK may be mediated by direct dephosphorylation of c-Raf and MEK by exogenous PTEN protein phosphatase activity in MDA-MB-468 PTEN cells, or by the perturbation of other signaling pathways responsible for Raf/MEK phosphorylation by expression of PTEN. Indeed, it has been reported that the protein phosphatase activity of PTEN blocks Sp1 phosphorylation by inactivation of Erk, MEK and PKC, which is eventually involved in the downregulation of IGF-II expression in hepatoma cell lines (29) .
PI3K/Akt signaling and MEK/Erk signaling are the main processes involved in the induction of proliferation in many types of cells. Because of the blockade of functional PI3K/ Akt signaling by PTEN expression, MDA-MB-468 PTEN cells depend more on the MEK/Erk pathway (i.e., addiction to MEK/Erk signaling). As such, the treatment of MDA-468-PTEN cells with U0126, which blocks the MEK/Erk pathway, contributes to stronger suppression of cell growth and induction of apoptotic cell death as a result of blocking both the PI3K/Akt and MEK/Erk signaling pathways. In line with our data, it was recently reported that loss of PTEN markedly decreased the response to MEK inhibition in basal-like cancer cells (including MDA-MB-468 cells), and that combined inhibition of both PI3K and MEK synergistically inhibited the growth of basal-like breast cancer cells both in vitro and in vivo (30) . Basal-like breast cancers are a subtype of breast cancer receiving this name due to the resemblance of their gene expression profile to that of the normal breast epithelial cells (31) . Absence of both functional nuclear hormone receptors and HER2 gene amplification are characteristics of basal-like breast cancers; hence, this subtype of the disease is often called 'triple-negative' breast cancer (32) . Fig. 7 indicates that MDA-MB-231 cells expressing endogenous PTEN were more sensitive to MEK/Erk inhibition by U0126 than ZR-75-1 cells, which express very low levels of endogenous PTEN. Of note, the percentage inhibition of cell growth is shown in Fig. 7 , as there is a big difference in growth rates between MDA-MB-231 and ZR-75-1, making it difficult to compare the two directly. Again, p-Erk levels in ZR-75-1 cells were not affected by U0126, while p-Erk levels in MDA-MB-231 cells were significantly reduced by U0126. These data confirm that both endogenous and exogenous PTEN are capable of conferring sensitivity to U0126. Indeed, among basal-like breast cancer cells, PTEN-null cells (such as MDA-MB-468, HCC1395, BT-549, CAL-148, HCC1937, HCC38, and MDA-MB-436) have a higher EC50 concentration for MEK inhibitor, compared to PTEN wild-type cells (including MDA-MB-144VI, HDQ-P1, DU4475, HCC1806, MDA-MB-231, HCC1143 and BT20) (30) .
In conclusion, our study demonstrates that the presence of PTEN confers sensitivity to MEK/Erk inhibition for the blockade of cell proliferation and down-regulation of p-Erk levels in basal-like breast cancer MDA-MB-468 cells. Combination treatment with PI3K/Akt inhibitors and MEK/ Erk inhibitors could be a potentially effective therapeutic strategy for basal-like triple-negative breast cancers without a target molecule, such as estrogen receptor or HER2, for a tailored therapeutic approach.
